Literature DB >> 29069409

Initial 2-year results of CardioCel® patch implantation in children.

Carine Pavy1, Guido Michielon1, Jan Lukas Robertus2, François Lacour-Gayet1, Olivier Ghez1.   

Abstract

OBJECTIVES: We present the initial 2-year results of CardioCel® patch (Admedus Regen Pty Ltd, Perth, WA, Australia) implantation in paediatric patients with congenital heart diseases.
METHODS: This was a single-centre retrospective study with prospectively collected data of all patients aged 18 years and under operated for congenital heart disease. The patch was introduced in 2014, with clinical practice committee approval and a special consent in case of an Ozaki procedure. Standard follow-up was performed with systematic clinical exams and echocardiograms. In case of reoperation or graft failure, the patch was removed and sent for a histological examination.
RESULTS: Between March 2014 and April 2016, 101 patients had surgical repair using a CardioCel patch. The mean age was 22 (±36.3) months, and the mean weight was 9.7 (±10.3) kg. No infections and no intraoperative implantation difficulties were associated with the patch. The median follow-up period was 212 (range 4-726) days. The overall 30-day postoperative mortality was 3.8% (n = 4), none of which were related to graft failure. Five children were reoperated because of graft failure, 4 of whom had the patch implanted for aortic and were aged less than 10 days. The indications for patch implantation in the aortic position were aortopulmonary window, truncus arteriosus, coarctation and aortic arch hypoplasia repair. The median time between the first and the second operation for graft failure was 245 (range 5-480) days.
CONCLUSIONS: Our experience shows that the patch is well tolerated in the septal, valvar and pulmonary artery positions. However, we experienced graft failures in infants in the aortic position.
© The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29069409     DOI: 10.1093/icvts/ivx295

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

Review 1.  Bioengineering Human Tissues and the Future of Vascular Replacement.

Authors:  Mehmet H Kural; Yuling Li; Juan Wang; Kaleb M Naegeli; Emmanuelle A Hugentobler; Laura E Niklason
Journal:  Circ Res       Date:  2022-06-23       Impact factor: 23.213

2.  Industrial Processing Induces Pericardial Patch Degeneration.

Authors:  Armin Darius Peivandi; Sven Martens; Barbara Heitplatz; Alena Guseva; Klaus-Michael Mueller; Sabrina Martens
Journal:  Front Surg       Date:  2022-05-27

3.  Evaluation of a polyurethane-reinforced hydrogel patch in a rat right ventricle wall replacement model.

Authors:  Ze-Wei Tao; Siliang Wu; Elizabeth M Cosgriff-Hernandez; Jeffrey G Jacot
Journal:  Acta Biomater       Date:  2019-10-22       Impact factor: 8.947

4.  Vascular Remodeling of Clinically Used Patches and Decellularized Pericardial Matrices Recellularized with Autologous or Allogeneic Cells in a Porcine Carotid Artery Model.

Authors:  Jaroslav Chlupac; Roman Matejka; Miroslav Konarik; Robert Novotny; Zuzana Simunkova; Iveta Mrazova; Ondrej Fabian; Milan Zapletal; Zdenek Pulda; Jan Falk Lipensky; Jana Stepanovska; Karel Hanzalek; Antonin Broz; Tomas Novak; Alena Lodererova; Ludek Voska; Theodor Adla; Jiri Fronek; Miroslav Rozkot; Serhiy Forostyak; Peter Kneppo; Lucie Bacakova; Jan Pirk
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

5.  Reconstruction of the Aortic Arch in Neonates and Infants: The Importance of Patch Material.

Authors:  Ingrid M van Beynum; Serife Kurul; Thomas Krasemann; Michiel Dalinghaus; Pieter van de Woestijne; Jonathan R Etnel; Ad J J C Bogers
Journal:  World J Pediatr Congenit Heart Surg       Date:  2021-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.